Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


29.01.2024

1 Acta Haematol
1 Am J Clin Oncol
6 Am J Hematol
5 Ann Hematol
5 Blood
2 BMC Cancer
3 Bone Marrow Transplant
2 Br J Cancer
1 Cancer
1 Cancer Lett
1 Cancer Res
2 Int J Hematol
1 J Pediatr Hematol Oncol
5 Leuk Lymphoma
3 Leukemia


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Haematol

  1. HU GH, Zhang XH, Liu KY, Xu LP, et al
    Outcome and prognostic factors of haploidentical allogeneic hematopoietic stem cell transplantation in pediatric relapsed or refractory ETV6/RUNX1-positive acute lymphoblastic leukemia.
    Acta Haematol. 2024 Jan 20. doi: 10.1159/000536396.
    PubMed         Abstract available


    Am J Clin Oncol

  2. AGUIAR-BUJANDA D, Croissier-Sanchez L, Perez-Cabrera D, Galvan-Ruiz S, et al
    Second Hematologic Malignancies Associated With Primary Mediastinal Germ Cell Tumors: A Population-based Study.
    Am J Clin Oncol. 2024;47:58-63.
    PubMed         Abstract available


    Am J Hematol

  3. CAMPANELLA A, Capasso A, Heltai S, Taccetti C, et al
    Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
    Am J Hematol. 2024 Jan 24. doi: 10.1002/ajh.27218.
    PubMed         Abstract available

  4. IM A, Quann K, Agha M, Raptis A, et al
    Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
    Am J Hematol. 2024 Jan 22. doi: 10.1002/ajh.27212.
    PubMed         Abstract available

  5. KURITA N, Imahashi N, Chiba S, Tanaka M, et al
    Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry-based study.
    Am J Hematol. 2024;99:236-244.
    PubMed         Abstract available

  6. GURNARI C, Pascale MR, Vitale A, Diral E, et al
    Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
    Am J Hematol. 2024;99:254-262.
    PubMed         Abstract available

  7. DINARDO CD
    Toward an improved understanding of hypomethylating agent and venetoclax therapies.
    Am J Hematol. 2024;99:152-154.
    PubMed        

  8. BRUNNER AM, Esteve J, Porkka K, Knapper S, et al
    Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
    Am J Hematol. 2024;99:E32-E36.
    PubMed         Abstract available


    Ann Hematol

  9. GABELLIER L, Peterlin P, Thepot S, Hicheri Y, et al
    Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
    Ann Hematol. 2024 Jan 26. doi: 10.1007/s00277-024-05623.
    PubMed         Abstract available

  10. CHATTOPADHYAY S, Lionel S, Selvarajan S, Devasia AJ, et al
    Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival.
    Ann Hematol. 2024 Jan 20. doi: 10.1007/s00277-024-05621.
    PubMed         Abstract available

  11. WANG J, Zhang H, Zhang R
    BRCA2 germline mutation in familial leukaemia with familial breast cancer: a case report.
    Ann Hematol. 2024;103:685-687.
    PubMed        

  12. BRUNNER A, Thalhammer-Thurner GC, Willenbacher W, Haun M, et al
    In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation.
    Ann Hematol. 2024;103:553-563.
    PubMed         Abstract available

  13. FERNANDEZ-LUIS S, Gomez Lamas D, Cerezo Martin JM, Mora Barrios JM, et al
    Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age.
    Ann Hematol. 2024;103:583-591.
    PubMed         Abstract available


    Blood

  14. BARATA JT
    Darwin, MSI2, and relapse in T-ALL.
    Blood. 2024;143:294-296.
    PubMed        

  15. SCHRAW JM
    Anticancer drug exposure in utero and leukemia.
    Blood. 2024;143:293-294.
    PubMed        

  16. GU H, Chen C, Hou ZS, He XD, et al
    PI3Kgamma maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway.
    Blood. 2024 Jan 25:blood.2023022202. doi: 10.1182/blood.2023022202.
    PubMed         Abstract available

  17. SAHASRABUDHE KD, Mims AS
    MRD in AML: who, what, when, where, and how?
    Blood. 2024;143:296-298.
    PubMed        

  18. OTHMAN J, Tiong IS, O'Nions J, Dennis M, et al
    Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
    Blood. 2024;143:336-341.
    PubMed         Abstract available


    BMC Cancer

  19. SHAPOURIAN H, Ghanadian M, Eskandari N, Shokouhi A, et al
    TIM-3/Galectin-9 interaction and glutamine metabolism in AML cell lines, HL-60 and THP-1.
    BMC Cancer. 2024;24:125.
    PubMed         Abstract available

  20. MA L, Wang Q, Li X, Shang Y, et al
    Development of a risk assessment model for cardiac injury in patients newly diagnosed with acute myeloid leukemia based on a multicenter, real-world analysis in China.
    BMC Cancer. 2024;24:132.
    PubMed         Abstract available


    Bone Marrow Transplant

  21. XIAO M, Zhou J, Zhu X, He Y, et al
    A prognostic score system in adult T-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Jan 24. doi: 10.1038/s41409-024-02211.
    PubMed         Abstract available

  22. CHEN W, Shi J, Luo Y, Yu J, et al
    Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma.
    Bone Marrow Transplant. 2024 Jan 23. doi: 10.1038/s41409-023-02191.
    PubMed        

  23. ALBINGER N, Muller S, Kostyra J, Kuska J, et al
    Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia.
    Bone Marrow Transplant. 2024 Jan 22. doi: 10.1038/s41409-023-02180.
    PubMed         Abstract available


    Br J Cancer

  24. ZAKKAK N, Barclay ME, Swann R, McPhail S, et al
    The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit.
    Br J Cancer. 2024;130:297-307.
    PubMed         Abstract available

  25. GUTIERREZ-CAMINO A, Richer C, Ouimet M, Fuchs C, et al
    Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
    Br J Cancer. 2024;130:317-326.
    PubMed         Abstract available


    Cancer

  26. SEDETA E, Jemal A, Nisotel L, Sung H, et al
    Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
    Cancer. 2024 Jan 20. doi: 10.1002/cncr.35214.
    PubMed         Abstract available


    Cancer Lett

  27. YANG F, Cui X, Wang H, Zhang D, et al
    Iron overload promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of FOS.
    Cancer Lett. 2024 Jan 17:216652. doi: 10.1016/j.canlet.2024.216652.
    PubMed         Abstract available


    Cancer Res

  28. SU Y, Carter JL, Li X, Fukuda Y, et al
    The imipridone ONC213 targets alpha-ketoglutarate dehydrogenase to induce mitochondrial stress and suppress oxidative phosphorylation in acute myeloid leukemia.
    Cancer Res. 2024 Jan 24. doi: 10.1158/0008-5472.CAN-23-2659.
    PubMed         Abstract available


    Int J Hematol

  29. OKAYAMA Y, Harada N, Makuuchi Y, Kuno M, et al
    Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission.
    Int J Hematol. 2024 Jan 22. doi: 10.1007/s12185-023-03707.
    PubMed         Abstract available

  30. UEKI H, Ogawa C, Goto H, Nishi M, et al
    TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia.
    Int J Hematol. 2024 Jan 25. doi: 10.1007/s12185-024-03710.
    PubMed         Abstract available


    J Pediatr Hematol Oncol

  31. TERZI O, Bayram C, Solgun HA, Yildirgan D, et al
    Raccoon Eyes Presentation in a Child Diagnosed With Acute Lymphoblastic Leukemia: A Case Report.
    J Pediatr Hematol Oncol. 2024 Jan 29. doi: 10.1097/MPH.0000000000002813.
    PubMed         Abstract available


    Leuk Lymphoma

  32. TADMOR T, Levy Yurkovski I
    Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia.
    Leuk Lymphoma. 2024 Jan 22:1-4. doi: 10.1080/10428194.2024.2304026.
    PubMed        

  33. FU S, Alhaj Z, Huynh D
    Prevalence of primary chronic lymphocytic leukemia in the United States: a cross-sectional study using the SEER database.
    Leuk Lymphoma. 2024 Jan 22:1-2. doi: 10.1080/10428194.2023.2300714.
    PubMed        

  34. EL-ASHWAH S, Salmanton-Garcia J, Bilgin YM, Itri F, et al
    The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
    Leuk Lymphoma. 2024;65:199-208.
    PubMed         Abstract available

  35. JOHNSON SM, Haberberger J, Galeotti J, Ramkissoon L, et al
    Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms.
    Leuk Lymphoma. 2024;65:209-218.
    PubMed         Abstract available

  36. ITONAGA H, Kato T, Sawayama Y, Katsuoka S, et al
    RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL.
    Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276058.
    PubMed        


    Leukemia

  37. TAN SH, Tan TK, Yokomori R, Liao M, et al
    Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Jan 25. doi: 10.1038/s41375-023-02125.
    PubMed        

  38. TETTERO JM, Heidinga ME, Mocking TR, Fransen G, et al
    Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.
    Leukemia. 2024 Jan 25. doi: 10.1038/s41375-024-02158.
    PubMed         Abstract available

  39. APPELBAUM JS, Wei AH, Mandrekar SJ, Tiong IS, et al
    Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
    Leukemia. 2024 Jan 23. doi: 10.1038/s41375-024-02143.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.